We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting children. The company received accelerated approval for Exondys 51, Amondys 45 (casimersen) and Vyondys 53 (golodirsen). Exondys 51 is Sarepta's first PMO-based technology to be granted accelerated approval by the FDA. The company is conducting a confirmatory study on the clinical benefits of these drugs for gaining continued approval. The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051. Sarepta is also developing gene therapies for treating DMD, Limb-girdle muscular dystrophy and central nervous system disorders including Mucopolysaccharidosis type IIIA and Pompe Disease.
- Recent SRPT Stock Price: $122.69
- Yearly Gain for SRPT stock: 84.69%
- Market Cap for SRPT stock: $12.80B
- P/E Ratio for SRPT stock: -18.63
Will SRPT's stock price go up? Is there an accurate SRPT stock forecast available?
TipRanks.com reports that Sarepta Therapeutics currently has 19 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $167.53. The target pricing ranges from a high SRPT forecast of $206.00 down to a low forecast of $125.00. Sarepta Therapeutics (SRPT)’s last closing stock price was $122.69 which would put the average price target at 36.55% upside.
In addition, TradingView issued a Sell rating for SRPT stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on SRPT stock.
Other analysts covering SRPT include:
- Kristen Kluska of Cantor Fitzgerald issued a Buy rating with the price target of $ 165 on 23 hours ago
- Judah Frommer of Credit Suisse issued a Hold rating with the price target of $ 139 on 23 hours ago
- Zhiqiang Shu of Berenberg Bank issued a Hold rating with the price target of $ 139 on 23 hours ago
- Yun Zhong of BTIG issued a Buy rating with the price target of $ 160 on 23 hours ago
If you are wondering if SRPT is a good stock to buy, here are 3rd party ratings for SRPT stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 37% (92 out of 249)
What is the sentiment on the street regarding Sarepta Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for SRPT stock: Very Bullish
- Blogger Consensus for SRPT stock: Bullish
- Media Buzz for SRPT stock: Medium
- Insider Signal for SRPT stock: Positive
- Investor Sentiment for SRPT stock: Very Positive
- Hedge Fund signal for SRPT stock: Negative
The stock market is extremely volatile, and you need to do your own research on SRPT stock including scouring the social networks like SRPT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SRPT stock chart >>
Summary: Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.
- Recent DGX Stock Price: $131.53
- Yearly Gain for DGX stock: -5.86%
- Market Cap for DGX stock: $14.79B
- P/E Ratio for DGX stock: 16.931
Will DGX's stock price go up? Is there an accurate DGX stock forecast available?
TipRanks.com reports that Quest Diagnostics currently has 9 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $154.56. The target pricing ranges from a high DGX forecast of $166.00 down to a low forecast of $140.00. Quest Diagnostics (DGX)’s last closing stock price was $131.53 which would put the average price target at 17.51% upside.
In addition, TradingView issued a Strong Sell rating for DGX stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on DGX stock.
Other analysts covering DGX include:
- David S Macdonald of Truist Financial issued a Hold rating with the price target of $ 160 on 23 hours ago
- Ann Hynes of Mizuho Securities issued a Buy rating with the price target of $ 165 on 23 hours ago
- Derik De Bruin of Bank of America Securities issued a Buy rating with the price target of $ 166 on 23 hours ago
- Timothy Daley of Wells Fargo issued a Hold rating with the price target of $ 140 on 1 month ago
If you are wondering if DGX is a good stock to buy, here are 3rd party ratings for DGX stock:
- TipRanks.com: Hold
- TradingView.com: Strong Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Bottom 41% (147 out of 249)
What is the sentiment on the street regarding Quest Diagnostics? (Current ratings compiled by TipRanks.com)
- News Sentiment for DGX stock: Very Bullish
- Blogger Consensus for DGX stock: Bullish
- Media Buzz for DGX stock: Medium
- Insider Signal for DGX stock: ―
- Investor Sentiment for DGX stock: Negative
- Hedge Fund signal for DGX stock: Negative
The stock market is extremely volatile, and you need to do your own research on DGX stock including scouring the social networks like DGX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for DGX stock chart >>
Summary: Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif.
- Recent ACET Stock Price: $7.43
- Yearly Gain for ACET stock: -52.52%
- Market Cap for ACET stock: $330.38M
- P/E Ratio for ACET stock: -4.515
Will ACET's stock price go up? Is there an accurate ACET stock forecast available?
TipRanks.com reports that Adicet Bio currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $26.40. The target pricing ranges from a high ACET forecast of $38.00 down to a low forecast of $19.00. Adicet Bio (ACET)’s last closing stock price was $7.43 which would put the average price target at 255.32% upside.
In addition, TradingView issued a Sell rating for ACET stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ACET stock.
Other analysts covering ACET include:
- Soumit Roy of JonesTrading issued a Buy rating with the price target of $ 25 on 1 day ago
- Robert Driscoll of Wedbush issued a Buy rating with the price target of $ 30 on 1 day ago
- Edward White of H.C. Wainwright issued a Buy rating with the price target of $ 38 on 1 day ago
- Michael Schmidt of Guggenheim issued a Buy rating with the price target of $ 20 on 2 months ago
If you are wondering if ACET is a good stock to buy, here are 3rd party ratings for ACET stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 37% (92 out of 249)
What is the sentiment on the street regarding Adicet Bio? (Current ratings compiled by TipRanks.com)
- News Sentiment for ACET stock: Very Bullish
- Blogger Consensus for ACET stock: Bullish
- Media Buzz for ACET stock: High
- Insider Signal for ACET stock: ―
- Investor Sentiment for ACET stock: Very Negative
- Hedge Fund signal for ACET stock: Neutral
The stock market is extremely volatile, and you need to do your own research on ACET stock including scouring the social networks like ACET StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ACET stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
